radiosynovectomy efficacy in hemophilia patients

Rhenium-188 radiosynovectomy for chronic hemophilic knee synovitis: evaluation of its efficacy in hemophilia patients and establishment of radiosynovectomy at Clinical Joint Care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180702040304N1

Enrollment

Registered

2018-09-16

Start date

2018-05-24

Completion date

Unknown

Last updated

2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hemophilia A. Condition 2: Hemophilia B. Hereditary factor VIII deficiency Hereditary factor IX deficiency

Interventions

Prior to the injection, an appropriate dose is injected with a target of 100% blood level.Under aseptic conditions, after anesthetizing skin, subcutaneous and joint capsule with a suitable dose of lid

for washing the needle from the radioactive substance and not wasting it, needle washed with 2 ml saline.while the injection continues, needle is pulled out.Then the pressure is directly applied to th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Hemophilia A and B with at least 2 episodes per month

Exclusion criteria

Exclusion criteria: Patients with joint ankylosis and radiological evidences of joint degeneration

Design outcomes

Primary

Measure	Time frame
Synovial thickness. Timepoint: At the beginning of the study and 6 months after intra-articular injection. Method of measurement: Magnetic Resonance Imaging.	—

Secondary

Measure	Time frame
The amount of pain in activity and rest. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Visual Analogue Scale.;The number of intra-articular hemorrhages per month. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Interview with patient.;The amount of articular changes in MRI. Timepoint: At the beginning of the study and 6 months after the intervention. Method of measurement: Denver Mri score.;Coagulation factor consumption in month. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Interview with patient.;Level of patient performance. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Functional Independence in Hemophilia (FISH) questionnaire.;The amount of articular changes in X-ray radiography. Timepoint: At the beginning of the study and 6.12 months after the intervention. Method of measurement: Petterson’s score.	—

Measure

Time frame

The amount of pain in activity and rest. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Visual Analogue Scale.;The number of intra-articular hemorrhages per month. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Interview with patient.;The amount of articular changes in MRI. Timepoint: At the beginning of the study and 6 months after the intervention. Method of measurement: Denver Mri score.;Coagulation factor consumption in month. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Interview with patient.;Level of patient performance. Timepoint: At the beginning of the study and 1,3,6,12 months after the intervention. Method of measurement: Functional Independence in Hemophilia (FISH) questionnaire.;The amount of articular changes in X-ray radiography. Timepoint: At the beginning of the study and 6.12 months after the intervention. Method of measurement: Petterson’s score.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Heidari

Mashhad University of Medical Sciences

Heidaria931@mums.ac.ir+98 51 3841 7453

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026